La Hiperlipidemia significa cantidad o concentración excesiva de lípidos o grasas en sangre o más exactamente de colesterol y/o de triglicéridos con respecto a los valores normales.
Los valores elevados de lípidos en sangre resultan muy comunes en las analíticas bioquímicas de rutina.
La hiperlipidemia posee muy diversas causas, desde genéticas a autoinmunes sin embargo un elevado porcentaje de hiperlipidemias son el resultado de una mala alimentación.
Por lo tanto la manera de tratar el exceso de triglicéridos o colesterol en sangre es incidir sobre la causa que ha alterado dichos niveles y cambiar los hábitos alimenticios o modo de vida como el estrés o el tabaquismo.
Mediante Micoterapia Maitake Reishi y Shiitake resultan los hongos con mayor poder hipolipemiante.
El extracto de Maitake (Grifola frondosa) ha demostrado poseer actividad antihipertensiva, antidiabética, antiobesidad y efecto antihiperlipidémico, mediante disminución de colesterol total y LDL, siendo especialmente recomendado para tratar el hígado graso.
El extracto de Shiitake posee un importante efecto hipocolesterolemiante usado como complemento de la dieta. Es uno de los hongos con mayor actividad en la prevención de depósito de colesterol en las paredes vasculares y por tanto en la formación de la placa de ateroma. Posee un efecto preventivo frente a las patologías cardiovasculares de una manera indirecta
La fracción polisacárida de Reishi resulta eficaz como agente hiperlipemiante e hipoglucemiante. Contiene ácidos ganodéricos que inhiben la síntesis de colesterol endógeno, el LDL y los triglicéridos.
La acción combinada de Reishi+ Shiitake+ Maitake fue originalemente diseñada para el tratamiento de personas con síntomas propios del Síndrome Metabólico, obesidad, hiperglucemia, hiperlipidemias e hipertensión
Askorbato k-HdTPowered + Mix-HdT
El Askorbato k-HdTPowered debe preceder a la toma del resto de los hongos.
En ayunas, toma una cápsula de Askorbato k-HdTPowered y a los cinco minutos una cápsula de Mix-HdT
|Askorbato k- HdTPowered||1||1||0||Biodisponibilidad|
Duración del tratamiento: Mínimo seis meses.
El protocolo clínico expuesto está basado en las recomendaciones generales estipuladas por el Instituto Internacional de Micoterapia (IMI) y deberá ser consultado por cada profesional para el uso de complementos elaborados a base de extractos de hongos. Será responsabilidad del facultativo variar la prescripción y la posología en función de su criterio médico así como de los síntomas y signos clínicos de cada paciente.
Title/Título: Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) fiber, and enokitake (Flammulina velutipes) fiber in rats
Author(s)/Autor(es): Fukushima M., Ohashi T., Fujiwara Y., Sonoyama K., Nakano M.. Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) fiber, and enokitake (Flammulina velutipes) fiber in rats. Experimental Biology and Medicine 226:758-765 (2001)
Abstract/Resumen: The effects of mushroom fibers on serum cholesterol and hepatic low-density lipoprotein (LDL) receptor mRNA in rats were investigated. Rats were fed a cholesterol-free diet with 50 g/kg cellulose powder (CP), 50 g/kg maitake (Grifola frondosa) fiber (MAF), 50 g/kg shiitake (Lentinus edodes) fiber (SF), or 50 g/kg enokitake (Flammulina velutipes) fiber (EF) for 4 weeks. There were no significant differences in the body weight, food intake, liver weight, cecum weight, and cecum pH among the groups. Cecal acetic acid, butyric acid, and total short-chain fatty acid (SCFA) concentrations in the SF and EF groups were significantly higher than those in the other groups. The serum total cholesterol concentration in the CP group was significantly higher than that in the MAF and EF groups. The very LDL (VLDL) + intermediate-density lipoprotein (IDL) + LDL-cholesterol concentration in the CP group was significantly higher than that in the MAF, SF, and EF groups, whereas the high-density lipoprotein (HDL)-cholesterol concentration in the EF group was significantly ower than that in the other groups at the end of the 4-week feeding period. The hepatic LDL receptor mRNA level in the EF group was significantly higher than that in the CP group. The fecal cholesterol excretion in the MAF, SF, and EF groups was significantly higher than that in the CP group. The results of this study demonstrate that MAF and EF lowered the serum total cholesterol level by enhancement of fecal cholesterol excretion, and in particular, by enhancement of hepatic LDL receptor mRNA in EF group
Title/Título: Glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from Grifola frondosa, and a method for preparing same
Author(s)/Autor(es): Zhuang C., Kawagishi C., Harry G. Glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from Grifola frondosa, and a method for preparing same. United States Patent 7214778
Abstract/Resumen: A glycoprotein extracted from the fruiting body of Grifola frondosa is demonstrated to have antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects, and has great potential as an active component for pharmaceuticals, dietary supplements or health food preparations to treat and/or prevent the above diseases. This invention is to provide the glycoprotein and its preparation method.
Title/Título: The Effects of Hot Water Soluble Polysaccharides from Lentinus edodes on Lipid Metabolism in the Rats Fed Butter Yellow
Author(s)/Autor(es): Choi M.Y., Lim S.S..The Effects of Hot Water Soluble Polysaccharides from Lentinus edodes on Lipid Metabolism in the Rats Fed Butter Yellow. J. Korean Soc. Food Sci. Nutr. Serial ID – ISSN1126-3311 Serial numberv. 29(2) p. 294-299 Serial Date(2000)
Abstract/Resumen: The effects of hot water soluble polysaccharides (PS) of Lentinus edodes on the lipid components in the liver and plasma of the rats fed the butter yellow were investigated. Twenty four rats were divided into four groups and fed with the diet containing 15% casein, 30% sucrose and 10% soybean oil (basal diet; NO group), supplemented with butter yellow (BO group) or/and PS (NP, BP group). The contents of triglyceride and phospholipid in liver were significantly lower in BP group than BO group but the content of total lipid and total cholesterol were not significant difference between BO and BP. The concentrations of total cholesterol and triglyceride of plasma were significantly lower in BP than BO. As the results PS of Lentinus edodes prevent the triglyceride and cholesterol rise and then improve the lipid metabolism of rats fed the butter yellow.
Title/Título: A phase I/II study of ling zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in patients with type II diabetes mellitus.
Author(s)/Autor(es): Gao Y, Lan J, Dai X, Ye J, Zhou S. A phase I/II study of ling zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in patients with type II diabetes mellitus. Int. J.Med. Mushrooms 6, 2004, 33-39.
Abstract/Resumen: Animal studies have demonstrated that the polysaccharide fractions of Ganoderma lucidum (Ling Zhi, reishi mushroom) have potential hypoglycemic and hypolipidemic activities. This clinical study aimed to evaluate the efficacy and safety of Ganopoly (polysaccharide fractions extracted from G. lucidum by patented technique) in 71 patients with confirmed type II diabetes mellitus (DM). Eligibility criteria included type II DM of >3 months’ duration for which patients were not receiving insulin; age >18 years; normal vital signs for age and disease state; normal electrocardiogram (ECG); and fasting plasma glucose (FPG) level of 18.104.22.168 mmol/L in sulfonylurea-naive patients or an FPG <10 mmol/L before washout in sulfonylurea-treated patients. Patients were randomly grouped to be given either Ganopoly or placebo orally at 1800 mg three times daily for 12 weeks. Patients underwent 4 weeks of dose adjustment followed by 8 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA1c), plasma glucose, insulin, and C-peptide were monitered at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. The treatment of Ganopoly significantly decreased the mean HbA1c from 8.4 at baseline to 7.6% at 12 weeks. Significant changes in mean FPG and PPG levels at the last visit paralleled the changes in mean HbA1c levels. At baseline, the mean FPG and PPG values in patients treated with Ganopoly were 12.0 and 13.6 mmol/L, respectively. At week 12, mean PPG values had decreased to 11.8 mmol/L. However, these parameters did not change or slightly increased in patients receiving placebo. The between-group difference in PPG levels at week 12 was significant (p < 0.05). Changes in fasting insulin, 2-hour post-prandial insulin, fasting Cpeptide, and 2-hour post-prandial C-peptide were consistent, with the between-group differences in these end points being significant at the last visit. Overall, Ganopoly was well tolerated. This study demonstrated that Ganopoly was efficacious and safe in lowering blood glucose concentrations.
Title/Título: Ganoderma lucidum (Lingzhi), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study
Author(s)/Autor(es): Wachtel-Galor S., Tomlinson B., Benzie I.F. Ganoderma lucidum (Lingzhi), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 2004;91:263-9.
Abstract/Resumen: Lingzhi (Ganoderma lucidum) is a woody mushroom highly regarded in traditional medicine and is widely consumed in the belief that it promotes health and longevity, lowers the risk of cancer and heart disease and boosts the immune system. However, objective scientific validation of the putative health benefits of Lingzhi in human subjects is lacking, and issues of possible toxicity must be addressed. The present double-blinded, placebo-controlled, cross-over intervention study investigated the effects of 4 weeks Lingzhi supplementation on a range of biomarkers for antioxidant status, CHD risk, DNA damage, immune status, and inflammation, as well as markers of liver and renal toxicity. It was performed as a follow-up to a study that showed that antioxidant power in plasma increased after Lingzhi ingestion, and that 10 d supplementation was associated with a trend towards an improved CHD biomarker profile. In the present study, fasting blood and urine from healthy, consenting adults (n 18; aged 22–52 years) was collected before and after 4 weeks supplementation with a commercially available encapsulated Lingzhi preparation (1·44 g Lingzhi/d; equivalent to 13·2 g fresh mushroom/d) or placebo. No significant change in any of the variables was found, although a slight trend toward lower lipids was again seen, and antioxidant capacity in urine increased. The results showed no evidence of liver, renal or DNA toxicity with Lingzhi intake, and this is reassuring. The present study of the effects in healthy, well-nourished subjects provides useful, new scientific data that will support controlled intervention trials using atrisk subjects in order to assess the therapeutic effect of Lingzhi in the promotion of healthy ageing.